Luo, Rui
Chong, Weelic http://orcid.org/0000-0003-1639-0480
Wei, Qiang
Zhang, Zhenchao
Wang, Chun
Ye, Zhong
Abu-Khalaf, Maysa M.
Silver, Daniel P.
Stapp, Robert T.
Jiang, Wei
Myers, Ronald E.
Li, Bingshan
Cristofanilli, Massimo
Yang, Hushan http://orcid.org/0000-0001-9920-1731
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA207468)
Article History
Received: 23 September 2020
Accepted: 11 May 2021
First Online: 1 June 2021
Competing interests
: M.M.A. received honorarium for a consultant/advisory role from AstraZeneca, Immunomedics, PUMA, Biothera, Biotheranostics, Agendia, Norvartis, and Lilly. M.C. received honorarium from Lilly, Menarini, Foundation Medicine, CytoDyn, G1 Therapeutics, and Sermonix. H.Y. is on the SAB of Oriomics Inc., a shareholder of Illumina, Pfizer, and Oriomics, and serves as a NIH study section reviewer. The above reported activities were not related to the research reported in this article. The remaining authors declare no competing interests.